
AW-814141
CAS No. 905285-51-0
AW-814141( AW814141 )
Catalog No. M16508 CAS No. 905285-51-0
AW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAW-814141
-
NoteResearch use only, not for human use.
-
Brief DescriptionAW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β.
-
DescriptionAW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β; inhibits the release of TNF-alpha by lipopolysaccharide (LPS) treated human peripheral blood mononuclear cells with IC50 of 212 nM; inhibits paw swelling in CIA models.
-
In Vitro——
-
In Vivo——
-
SynonymsAW814141
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number905285-51-0
-
Formula Weight375.476
-
Molecular FormulaC22H25N5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-(hexahydrocyclopenta(c)pyrrol-2-ylamino)-8-methyl-6-o-tolyl-8H-pyrido(2,3-d)pyrimidine-7-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chopra P, et al. Int Immunopharmacol. 2010 Apr;10(4):467-73.
molnova catalog



related products
-
Emprumapimod
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
-
APS6-45
APS6-45 inhibits RAS/MAPK signaling and exhibits anti-tumor activity.
-
Dehydrocorydaline ch...
Dehydrocorydaline chloride is an alkaloid with anti-inflammatory and anti-cancer activity. Can improve the activation of p38 MAPK.